Research Triangle Park
-
Clinical Trials Tech Firm Science 37 to Go Private at Fraction of Past $1B Valuation
Science 37 rode the trends of Covid-19 technologies and SPAC mergers to a more than $1 billion valuation. But revenue for the decentralized clinical trials software firm stopped growing, and it’s now going private valued at just $38 million.
-
A One-Time Treatment for NASH? Kriya Strikes Deal for Liver Disease Gene Therapy
Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer
G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.
-
For Neuro Biotech Lusaris, Depression Therapy Starts by Lifting the Tongue
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
-
FDA finally signs off on Fennec Pharma drug for chemo-caused hearing loss in kids
A Fennec Pharmaceuticals drug that prevents hearing loss in children receiving cancer treatment is now approved. The regulatory decision comes more than two years later than expected, but the company now claims its drug, Pedmark, is the first and only FDA-approved therapy for reducing the risk of chemotherapy-induced hearing loss in pediatric cancer patients.
-
Artificial Intelligence, BioPharma
Creyon Bio gets some green for a new take on AI and genetic meds R&D
Creyon Bio is the latest company to launch with artificial intelligence technology for drug R&D. The startup claims its technology can provide sufficient safety and toxicity data to enable a therapy to bypass the animal research currently needed before clinical trials.
-
Bayer paying up to $4B for gene therapy pioneer AskBio
The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson’s and congestive heart failure.
-
FDA OKs Cellex’s antibody-based test for Covid-19
The agency granted an emergency use authorization to the company for its test, which is meant to detect antibodies against SARS-CoV-2 in the blood. However, antibody testing has both advantages and disadvantages relative to the more common PCR assays.
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
When CEOs talk, but don’t really say anything
CEO of surgical robotics company TransEnterix talks of interactions with FDA that rejected its 510(k) application but refuses to divulge the reason that led to the agency’s negative decision frustrating analysts and investors.
-
Bivarus raises $2M to add staff for patient-centered analytics, roll out data visualization engine
New investor Hatteras Venture Partners and existing investor Excelerate Health Ventures co-led the round.
-
Cloud Pharmaceuticals eyeing $10 million round
It also projects $5 million in revenue this year.
-
Validic inks deal with Quintiles to do remote monitoring for clinical trials
The move will help Quintiles improve the frequently costly, lengthy recruitment process for clinical trials.